hematopoietic stem cell transplantation

$Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease$

Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

By MedXY 08/27/2026

This retrospective multicenter study evaluates fecal microbiota transplantation (FMT) for steroid-refractory acute graft-versus-host disease (aGvHD), demonstrating a 60.5% response at day 28 and highlighting FMT's potential as a safe and effective treatment option.

Hematology-Oncology news Pediatrics

Reassessing Total Body Irradiation in Young Children with ALL: Long-Term Safety and Outcomes

By MedXY 08/25/2026

A French longitudinal study finds no increased long-term complications or compromised quality of life in children under 4 years undergoing TBI-based HSCT for acute lymphoblastic leukemia, challenging prior age restrictions.

Hematology-Oncology news OB/GYN & Women’s Health

Ovarian Tissue Cryopreservation After Hematopoietic Stem Cell Transplantation: A Viable Fertility Preservation Strategy in Selected Females

By MedXY 08/20/2026

This study evaluates ovarian tissue cryopreservation (OTC) feasibility in girls and young women post-hematopoietic stem cell transplantation (HSCT), demonstrating OTC as a potential fertility salvage option despite reduced ovarian reserve after HSCT.

Hematology-Oncology news Pediatrics

Reduced-Intensity Thiotepa Plus Post-Transplant Cyclophosphamide Delivers Near-Universal Engraftment and Minimal GVHD in Matched Sibling Transplantation for Adolescents and Adults With Sickle Cell Disease

By MedXY 05/04/2026

A prospective multicenter study reports excellent survival, no graft failure, and very low GVHD with a thiotepa-based reduced-intensity matched sibling transplant platform for severe sickle cell disease.

Hematology-Oncology Nephrology news

Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis

By MedXY 02/22/2026

A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.

Hematology-Oncology news Pediatrics

Beyond the CNS and Skeleton: HSPC-Gene Therapy (OTL-203) Demonstrates Superior Multi-System Efficacy in Hurler Syndrome

By MedXY 01/20/2026

A clinical study comparing OTL-203 gene therapy to allogeneic HSCT for Hurler syndrome reveals significant improvements in corneal clarity, hearing preservation, and cardiac stability, marking a potential shift in the standard of care for multisystemic lysosomal storage disorders.

Hematology-Oncology news

Non‑conditioned Autologous Gene Therapy Reverses Bone Marrow Failure in Fanconi Anaemia‑A: FANCOLEN‑1 Phase 1/2 and Long‑Term Outcomes

By MedXY 11/11/2025

The FANCOLEN‑1 trial shows that infusion of autologous FANCA‑corrected CD34+ cells without cytotoxic conditioning produced sustained engraftment and clinical improvement in a majority of treated patients with Fanconi anaemia‑A, with an acceptable short‑term safety profile and no genotoxicity detected during follow‑up.

Clinical Updates Hematology-Oncology Specialties Transplantation

Multisite Randomized Trial of Inpatient Palliative Care in Hematopoietic Stem Cell Transplantation: Enhancing Patient and Caregiver Outcomes

By MedXY 09/09/2025

Inpatient palliative care during hematopoietic stem cell transplantation improves patients’ quality of life, reduces depression and PTSD symptoms, and offers sustained psychological benefits up to six months post-transplant.

Clinical Updates Hematology-Oncology news Specialties Transplantation

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

By MedXY 09/09/2025

Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for underrepresented patient groups.